• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Comtech Telecommunications Shares Are Trading Lower By Over 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session

    12/8/23 12:57:59 PM ET
    $AGRO
    $ALXO
    $ARVN
    $AUVI
    Farming/Seeds/Milling
    Consumer Staples
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AGRO alert in real time by email

    Shares of Comtech Telecommunications Corp. (NASDAQ:CMTL) moved lower during Friday’s session following weak quarterly earnings.

    Comtech Telecom posted adjusted earnings of 24 cents per share, missing market estimates of 26 cents per share. The company’s quarterly sales came in at $151.91 million versus expectations of $151.87 million.

    Comtech Telecommunications shares fell 16.4% to $10.45 on Friday.

    Here are some other stocks moving in today's mid-day session.

    Gainers

    • Intensity Therapeutics, Inc. (NASDAQ:INTS) shares jumped 149.2% to $10.32. Intensity Therapeutics presented INT230-6 data in early-stage breast cancer patients.
    • MBIA Inc. (NYSE:MBI) shares climbed 63.8% to $12.09 after the company announced it declared an extraordinary cash dividend on MBIA common stock of $8.00 per share.
    • ALX Oncology Holdings Inc. (NASDAQ:ALXO) gained 35.7% to $12.56. Jefferies upgraded ALX Oncology Holdings from Hold to Buy and raised the price target from $8 to $18.
    • VerifyMe, Inc. (NASDAQ:VRME) gained 27% to $1.29. VerifyMe’s board approved share repurchase program of up to $500,000.
    • Exicure, Inc. (NASDAQ:XCUR) shares rose 23.2% to $0.5297 after gaining more than 5% on Thursday.
    • Torrid Holdings Inc. (NYSE:CURV) gained 22.3% to $5.07 after the company reported better-than-expected third-quarter financial results and issued FY23 revenue guidance above estimates.
    • QuantaSing Group Limited (NASDAQ:QSG) surged 21.5% to $2.3201.
    • Loop Media, Inc. (NASDAQ:LPTV) climbed 20.4% to $1.00.
    • Volato Group, Inc. (NYSE:SOAR) rose 20.4% to $6.80.
    • Virco Mfg. Corporation (NASDAQ:VIRC) jumped 18.2% to $8.28 following third-quarter results.
    • MicroAlgo Inc. (NASDAQ:MLGO) rose 15% to $2.36.
    • Bitfarms Ltd. (NASDAQ:BITF) gained 15% to $2.46
    • Hello Group Inc. (NASDAQ:MOMO) gained 14.8% to $7.54 after reporting results for the third quarter.
    • Paramount Global (NASDAQ:PARA) rose 13.8% to $17.11.
    • Arvinas, Inc. (NASDAQ:ARVN) jumped 12.8% to $36.88. Arvinas and Pfizer recently announced interim data from the Phase 1b trial of Vepdegestrant in combination with Palbociclib.
    • Axos Financial, Inc. (NYSE:AX) gained 12.2% to $50.15. Axos closed purchase of two loan portfolios from the FDIC.
    • Eneti Inc. (NASDAQ:NETI) rose 10.3% to $10.83. Cadeler A/S and Eneti announced extension of share exchange offer for all outstanding shares of common stock of Eneti Inc. to Dec. 14, 2023.
    • Warner Bros. Discovery, Inc. (NASDAQ:WBD) gained 7.6% to $11.65.
    • Upstart Holdings, Inc. (NASDAQ:UPST) gained 7.2% to $36.29.
    • Lululemon Athletica Inc. (NASDAQ:LULU) shares gained 4.1% to $483.58. Lululemon reported upbeat results for its third quarter but issued a weak sales outlook for the current quarter.

    Losers

    • Cyngn Inc. (NASDAQ:CYN) shares fell 48.4% to $0.2065 after the company announced pricing of $5 million public offering of common stock of 33,333,333 shares at $0.15 per share.
    • African Agriculture Holdings Inc. (NASDAQ:AAGR) shares declined 33.6% to $3.00.
    • Golden Heaven Group Holdings Ltd. (NASDAQ:GDHG) fell 33.6% to $1.54. Golden Heaven Group shares dipped 89% on Thursday after the company announced that it intends to enter into an operating lease framework agreement with a top-tier Chinese amusement group.
    • Biomea Fusion, Inc. (NASDAQ:BMEA) fell 24.4% to $11.36. Biomea Fusion presented long-term follow-up data showing improved glycemic control after 22 weeks off treatment in ongoing Phase II study of BMF-219 in adults with Type 2 diabetes in poster presentation at WCIRDC.
    • Applied UV, Inc. (NASDAQ:AUVI) fell 21.6% to $0.0855. Applied UV announced a 1-for-25 reverse stock split.
    • HashiCorp, Inc. (NASDAQ:HCP) shares fell 21% to $19.68 after the company reported third-quarter financial results.
    • Veradigm Inc. (NASDAQ:MDRX) fell 19.8% to $10.10. Veradigm named Greg Garrison as Executive Chairman.
    • Neptune Wellness Solutions Inc. (NASDAQ:NEPT) dipped 17.8% to $0.3895.
    • Avid Bioservices, Inc. (NASDAQ:CDMO) shares fell 17.8% to $4.35 after the company reported weak quarterly results.
    • Delta Apparel, Inc. (NYSE:DLA) dipped 17.1% to $7.35 following fourth-quarter results.
    • RH (NYSE:RH) fell 13.4% to $243.49. RH posted an unexpected loss for its third quarter, while sales missed estimates.
    • Adecoagro S.A. (NYSE:AGRO) declined 13% to $10.43. JP Morgan downgraded Adecoagro from Neutral to Underweight and lowered the price target from $11.5 to $10.5.
    • Johnson Outdoors Inc. (NASDAQ:JOUT) dipped 12.5% to $47.65 after the company reported worse-than-expected fourth-quarter financial results.
    • Solid Biosciences Inc. (NASDAQ:SLDB) shares fell 10.1% to $5.18 after surging 68% on Thursday. The company announced that it received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its next-generation Duchenne muscular dystrophy gene therapy candidate known as SGT-003.
    • Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) dipped 10% to $211.99.
    • Troika Media Group, Inc. (NASDAQ:TRKA) shares fell 9.7% to $0.4850. Troika Media Group shares fell around 72% on Thursday after the company announced it filed for Chapter 11.
    • MINISO Group Holding Limited (NYSE:MNSO) declined 6.2% to $19.69.
    • Gates Industrial Corporation plc (NYSE:GTES) shares fell 5% to $11.64 as the company announced pricing of secondary offering of 15,000,000 ordinary shares.
    • GDS Holdings Limited (NASDAQ:GDS) fell 4.4% to $8.82. GDS secured a syndicated green financing facility of MYR1.27 billion to complete the next phase of Nusajaya Tech Park Data Center Campus development.

     

    Now Read This: 'I Like It Very Much': Jim Cramer Bullish On This Financial Stock Up 75% YTD

    Get the next $AGRO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGRO
    $ALXO
    $ARVN
    $AUVI

    CompanyDatePrice TargetRatingAnalyst
    Warner Bros. Discovery Inc.
    $WBD
    2/17/2026$31.00Buy → Neutral
    Rothschild & Co Redburn
    Upstart Holdings Inc.
    $UPST
    2/17/2026$30.00Sell → Neutral
    Compass Point
    Upstart Holdings Inc.
    $UPST
    2/13/2026$20.00Mkt Perform → Mkt Underperform
    Citizens
    Upstart Holdings Inc.
    $UPST
    2/13/2026$35.00Sell → Neutral
    Goldman
    Madrigal Pharmaceuticals Inc.
    $MDGL
    1/28/2026$964.00Overweight
    Barclays
    Bitfarms Ltd.
    $BITF
    1/27/2026$3.00Outperform → Mkt Perform
    Keefe Bruyette
    Warner Bros. Discovery Inc.
    $WBD
    1/14/2026$30.00Buy → Neutral
    Guggenheim
    Biomea Fusion Inc.
    $BMEA
    1/13/2026$8.00Buy
    Rodman & Renshaw
    More analyst ratings

    $AGRO
    $ALXO
    $ARVN
    $AUVI
    SEC Filings

    View All

    SEC Form 6-K filed by MINISO Group Holding Limited

    6-K - MINISO Group Holding Ltd (0001815846) (Filer)

    2/23/26 8:00:25 AM ET
    $MNSO
    Department/Specialty Retail Stores
    Consumer Discretionary

    SEC Form DFAN14A filed by Warner Bros. Discovery Inc.

    DFAN14A - Warner Bros. Discovery, Inc. (0001437107) (Subject)

    2/23/26 6:01:37 AM ET
    $WBD
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form DFAN14A filed by Warner Bros. Discovery Inc.

    DFAN14A - Warner Bros. Discovery, Inc. (0001437107) (Subject)

    2/20/26 7:04:29 PM ET
    $WBD
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $AGRO
    $ALXO
    $ARVN
    $AUVI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    RH UNVEILS 2026 INTERIORS SPRING SOURCEBOOK

    RH (NYSE:RH) announced today the release of the 2026 RH Interiors Spring Sourcebook, presenting nearly 600 pages of inspired design by internationally renowned designers, artisans and manufacturers. From monastic minimalism to interstellar illumination, the rhythm of reeding to a study in stone, the comprehensive design resource represents the brand's continued commitment to imagination, innovation and quality. To view the full announcement, please click here. ABOUT RH RH (NYSE:RH) is a global curator of design, taste and style in the luxury lifestyle market. Operating across the United States, Canada, the United Kingdom and Europe, the Company offers collections through its retail ga

    2/23/26 9:05:00 AM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    Arvinas to Participate in Upcoming Investor Conferences

    NEW HAVEN, Conn, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in four upcoming investor conferences: TD Cowen 46th Annual Health Care Conference on Tuesday, March 3. Management will participate in a fireside chat, available here, at 1:10 p.m. ET.Leerink Global Healthcare Conference on Monday, March 9. Management will participate in a fireside chat, available here, at 4:20 p.m. ET.Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10. Management will participate in a fireside chat, available here, at

    2/23/26 7:00:00 AM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    lululemon Announces 100th Store Opening in EMEA

    Milestone location will be the first lululemon store in Poland and will open with franchise partner Arion Retail Group lululemon (NASDAQ:LULU) today announced the upcoming opening of the 100th lululemon store in its Europe, Middle East, and Africa (EMEA) market, marking a significant milestone in the brand's international expansion journey. Across EMEA, lululemon stores are a blend of company- and franchise-operated locations, reflecting the brand's agile and considered approach to growth. Through its franchise partnership agreement with Arion Retail Group, the 100th lululemon location will open on March 13 in Warsaw, Poland, becoming the first lululemon store in the country. This 100th

    2/23/26 6:30:00 AM ET
    $LULU
    Apparel
    Consumer Discretionary

    $AGRO
    $ALXO
    $ARVN
    $AUVI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Warner Bros. Discovery downgraded by Rothschild & Co Redburn with a new price target

    Rothschild & Co Redburn downgraded Warner Bros. Discovery from Buy to Neutral and set a new price target of $31.00

    2/17/26 8:13:55 AM ET
    $WBD
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Upstart upgraded by Compass Point with a new price target

    Compass Point upgraded Upstart from Sell to Neutral and set a new price target of $30.00

    2/17/26 8:05:30 AM ET
    $UPST
    Finance: Consumer Services
    Finance

    Upstart downgraded by Citizens with a new price target

    Citizens downgraded Upstart from Mkt Perform to Mkt Underperform and set a new price target of $20.00

    2/13/26 8:31:11 AM ET
    $UPST
    Finance: Consumer Services
    Finance

    $AGRO
    $ALXO
    $ARVN
    $AUVI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, FINANCE AND CAO Pinto Shelly sold $1,283 worth of shares (565 units at $2.27), decreasing direct ownership by 0.64% to 87,708 units (SEC Form 4)

    4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

    2/20/26 4:01:02 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF EXECUTIVE OFFICER Lettmann Jason covered exercise/tax liability with 2,201 shares, decreasing direct ownership by 0.71% to 305,920 units (SEC Form 4)

    4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

    2/19/26 9:02:25 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Nick Mosich sold $124,950 worth of shares (1,275 units at $98.00), decreasing direct ownership by 2% to 79,942 units (SEC Form 4)

    4 - Axos Financial, Inc. (0001299709) (Issuer)

    2/19/26 6:30:55 PM ET
    $AX
    Savings Institutions
    Finance

    $AGRO
    $ALXO
    $ARVN
    $AUVI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for REZDIFFRA issued to MADRIGAL PHARMACEUTICALS INC

    Submission status for MADRIGAL PHARMACEUTICALS INC's drug REZDIFFRA (ORIG-1) with active ingredient RESMETIROM has changed to 'Approval' on 03/14/2024. Application Category: NDA, Application Number: 217785, Application Classification: Type 1 - New Molecular Entity

    3/14/24 3:35:50 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

    Submission status for RHODES PHARMS's drug DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE (ORIG-1) with active ingredient AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE has changed to 'Approval' on 01/13/2021. Application Category: ANDA, Application Number: 213111, Application Classification:

    1/18/21 5:24:40 AM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    FDA Approval for DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

    Submission status for RHODES PHARMS's drug DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE (ORIG-1) with active ingredient AMPHETAMINE ASPARTATE ; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE has changed to 'Approval' on 01/13/2021. Application Category: ANDA, Application Number: 213111, Application Classification:

    1/18/21 5:24:40 AM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    $AGRO
    $ALXO
    $ARVN
    $AUVI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Goodman Corey S bought $4,999,999 worth of shares (3,184,713 units at $1.57) (SEC Form 4)

    4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

    2/4/26 4:15:59 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Virtue Robert A bought $15,800 worth of Common Stock $.01 par value (2,500 units at $6.32), increasing direct ownership by 0.51% to 495,824 units (SEC Form 4)

    4 - VIRCO MFG CORPORATION (0000751365) (Issuer)

    1/13/26 5:29:20 PM ET
    $VIRC
    Industrial Specialties
    Consumer Discretionary

    Director Richardson Bradley C bought $13,009 worth of Common Stock $.01 par value (2,000 units at $6.50), increasing direct ownership by 6% to 37,754 units (SEC Form 4)

    4 - VIRCO MFG CORPORATION (0000751365) (Issuer)

    1/7/26 4:19:05 PM ET
    $VIRC
    Industrial Specialties
    Consumer Discretionary

    $AGRO
    $ALXO
    $ARVN
    $AUVI
    Leadership Updates

    Live Leadership Updates

    View All

    Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH

    SUZHOU, China and MÖLNDAL, Sweden, Feb. 11, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938) ("Ribo") and its subsidiary Ribocure Pharmaceuticals AB ("Ribocure") today announced that they have entered into an exclusive worldwide licensing agreement with Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) ("Madrigal") for six pre-clinical small interfering RNA (siRNA) programs for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The collaboration will utilize Ribo's validated liver targeting siRNA GalSTARTM platform to develop novel treatm

    2/11/26 6:25:00 AM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bitfarms Announces Board Chair Transition in Anticipation of U.S. Redomiciliation

    TORONTO, Ontario and NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Bitfarms Ltd. (NASDAQ/TSX:BITF) ("Bitfarms" or the "Company"), a North American energy and digital infrastructure company, today announced that Edie Hofmeister has been appointed as Chair of the Board of Bitfarms. This appointment supports Bitfarms' previously announced strategy of redomiciling to the United States. Ms. Hofmeister succeeds Brian Howlett who has served as Director since 2020, and Chairman since 2024. Mr. Howlett will continue to serve as an Independent Director. Ms. Hofmeister brings over two decades of extensive expertise in legal affairs, corporate governance, and business strategy, developed over years in

    1/14/26 7:00:00 AM ET
    $BITF
    Finance: Consumer Services
    Finance

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    $AGRO
    $ALXO
    $ARVN
    $AUVI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Avid Bioservices Inc.

    SC 13G - Avid Bioservices, Inc. (0000704562) (Subject)

    12/13/24 10:53:25 AM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Torrid Holdings Inc.

    SC 13G - Torrid Holdings Inc. (0001792781) (Subject)

    12/12/24 6:06:52 PM ET
    $CURV
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    SEC Form SC 13D filed by Exicure Inc.

    SC 13D - EXICURE, INC. (0001698530) (Subject)

    11/29/24 5:51:28 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGRO
    $ALXO
    $ARVN
    $AUVI
    Financials

    Live finance-specific insights

    View All

    MBIA Inc. Investor Conference Call to Discuss Full Year and Fourth Quarter 2025 Financial Results Scheduled for Friday, February 27 at 8:00 A.M. Eastern Time

    MBIA Inc. (NYSE:MBI) will host a webcast and conference call for investors on Friday, February 27 at 8:00 a.m. (ET) to discuss its full year and fourth quarter 2025 financial results and other issues related to the Company. The dial-in number for the call is 800-445-7795 in the U.S. and 785-424-1699 from outside the U.S. The conference call code is MBIAQ425. A live webcast of the conference call will also be accessible on www.mbia.com. The conference call will consist of brief comments on the full year and fourth quarter 2025 results followed by a question-and-answer session for investors. MBIA's financial results report and 10-K filing will become available after the market closes on Thu

    2/20/26 11:15:00 AM ET
    $MBI
    Property-Casualty Insurers
    Finance

    Warner Bros. Discovery to Report Fourth Quarter and Full Year 2025 Results on Thursday, February 26

    NEW YORK, Feb. 19, 2026 /PRNewswire/ -- Warner Bros. Discovery, Inc. (the "Company") (NASDAQ:WBD) today announced that it will report its fourth quarter and full year 2025 results on Thursday, February 26, 2026 before the market opens. Links to the live webcast of the conference call as well as the earnings materials will be available in the "Investor Relations" section of the Company's website at https://ir.wbd.com/ starting at approximately 7:00 a.m. ET. The Company will host a conference call at 8:00 a.m. ET that same day to discuss the results. A telephone replay of the call will be available approximately two hours after the completion of the call until March 5, 2026. The replay can be

    2/19/26 2:00:00 PM ET
    $WBD
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026

    SOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ((", ALX Oncology", , NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced plans to report its fourth quarter and full year 2025 financial results and a business update on Friday, February 27th, 2026 before market open. The company will host a teleconference in conjunction with its financial results press release. Fourth Quarter and Full Year 2025 Results Webcast Information Date & Time: Friday, February 27, 2026 at 5:30am PT / 8:30am ET Webcast Access: https://viavid.webcasts.com/starthere.

    2/19/26 8:30:00 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care